Delivery of Pfizer and BioNTech’s COVID-19 vaccine to combat the Omicron variant has been delayed by several weeks due to a slower-than expected data gathering process, BioNTech Chief Executive Ugur Sahin told Germany’s Bild on Thursday (Feb. 17).
Once the Omicron-targeted vaccine is ready, the company would assess whether it was still needed, Sahin said.
“If the wave ends, that does not mean it can’t begin again,” he told Bild in a video interview, adding that BioNTech was in a position to continue creating new vaccines as variants emerged if needed.
“I really don’t see the situation as dramatic anymore,” he added.